Reference is being made to the stock exchange release from 25 August 2022
regarding H1-2022 Reporting, where Arctic Bioscience announced that Clinical
Trial Application (CTA) for a Phase IIb clinical trial in mild-to-moderate
psoriasis with the investigational medicinal product (IMP) HRO350 was expected
to be submitted in Q3 2022.
Arctic Bioscience is planning to send the CTA within 2 weeks. Approval of CTA by
authorities will allow for the first patient to be enrolled in the Phase IIb
clinical trial as planned in Q4 2022.
As previously communicated, sites for the clinical trial with access to
sufficient number of patients to conduct the study are localized in five
European countries.
The Clinical Trial Application contains key information about the IMP HRO350 and
the planned clinical trial activities.
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Christer L. Valderhaug
CEO of Arctic Bioscience AS
Mobile: +47 920 84 601
Email: christer@arctic-bioscience.com
Jone R. Slinning
CFO of Arctic Bioscience AS
Mobile: +47 948 75 469
Email: jone@arctic-bioscience.com
About Arctic Bioscience
Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.
The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.
Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.
Arctic Bioscience is led by a team of highly competent people with experience in
developing marine oils and experience from global pharmaceutical companies.